Yikon Genomics

Changping District, China Founded: 2012 • Age: 14 yrs
NIPT and liquid biopsy tests are offered via next-generation sequencing.

About Yikon Genomics

Yikon Genomics is a Healthcare company based in China founded in 2012. NIPT and liquid biopsy tests are offered via next-generation sequencing. Yikon Genomics has raised $31.26 million across 1 funding round from investors including Bank of Communications, Yuexiu Capital and Zhongyuan Jiupai Fund. Its Indian entity Yikon Genomics India Private Limited reported revenue of β‚Ή5.10 Cr. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Burning Rock, Novogene Corporation and Zhejiang Nuhui Health Technology; 3 of its 3 listed competitors have raised funding.

Company details

Yikon Genomics was founded in 2012 in Changping District, China, within the genomics sector. Next-generation sequencing is applied to deliver non-invasive prenatal testing and liquid biopsy services. A proprietary MALBAC-NGS platform is utilized for targeted DNA amplification. Kits are supplied for pre-implantation genetic testing, SNP-based tumor profiling, HER2 assessment, and BRCA analysis. Liquid biopsy options are also available to support personalized cancer treatments.

Key Metrics
  • Indian entity revenue
    ₹5.10 Cr

    FY 2025 · +400% YoY

  • Indian entity net profit
    ₹1.60 Cr

    FY 2025 · 31% margin

  • Indian entity EBITDA
    ₹1.69 Cr

    FY 2025 · 33% margin

  • Total Equity Funding
    $31.26M (USD)

    in 1 rounds

  • Latest Funding Round
    $31.26M (USD), Series C

    Nov 2019

  • Investors

Funding Insights of Yikon Genomics

Yikon Genomics has successfully raised a total of $31.26M through 1 strategic funding round. The most recent funding activity was a Series C round of $31.26 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $31.26M
  • Total Rounds 1
  • Last Round Series C β€” $31.26M
  • First Round $31.26M

    (Nov 2019)

  • Investors Count 4

All 1 funding rounds of Yikon Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2019$31.26MSeries C–Jinhe Capital
Valuation history

4 investors in total: 4 institutional.

Investors in Yikon Genomics

Yikon Genomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Bank of Communications, Yuexiu Capital and Zhongyuan Jiupai Fund.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Yuexiu Capital is engaged in financial services and asset management.
yuexiufund.comGuangzhou, China
Commercial bank focused on communication science and technology
1908bankcomm.comShanghai, China
Premium access

Investor details for Yikon Genomics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Yikon Genomics India Private Limited (Yikon Genomics)

Yikon Genomics India Private Limited is the primary company behind Yikon Genomics. The board of Yikon Genomics India Private Limited currently have 2 directors; the longest-serving is Amol Pandurang Jadhav, appointed in 2023.

DirectorDesignationAppointedTenureEntity
Amol Pandurang Jadhav
DIN 10126621
Director21 Apr 20233 yrs 6 moYikon Genomics India Private Limited
Vishakha Amol Jadhav
DIN 10126622
Director21 Apr 20233 yrs 6 moYikon Genomics India Private Limited

People of Yikon Genomics

4 people are tracked at Yikon Genomics (2 in leadership, 2 in team).

NameRoleGroup
Nana Li
Director Of FASLeadership
Sijia Lu
CEOLeadership
Ella Sun
Senior Business Development ManagerTeam
Barbara Verduzco B.
Business Development ManagerTeam
Premium access

Complete people profiles for Yikon Genomics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Yikon Genomics

Figures of Yikon Genomics India Private Limited, the primary company behind Yikon Genomics, for FY 2025. Revenue was ₹5.10 Cr (+400% year on year). Net profit was ₹1.60 Cr (31% margin). EBITDA was ₹1.69 Cr (33% margin).

  • ₹5.10 CrRevenue · FY 2025 · +400% YoY
  • ₹1.60 CrNet profit · 31% margin
  • ₹1.69 CrEBITDA · 33% margin
  • ₹1 LakhPaid-up capital

Balance sheet, profit and loss, cash flow and ratios of Yikon Genomics India Private Limited are on its company page.

Premium access

Detailed financial statements for Yikon Genomics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Yikon Genomics

2 dated milestones of Yikon Genomics across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Yikon Genomics is founded.
  2. Funding First funding round of $31.3M.

Competitors of Yikon Genomics

Yikon Genomics has 3 listed competitors in our database, 3 of them funded. They include Burning Rock, Novogene Corporation and Zhejiang Nuhui Health Technology.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
brbiotech.com2014Guangzhou, China$203.32M
Personalized cancer diagnostics are developed using genomic big data analysis.
novogene.com2011Beijing, China$75M141
Genomic services and solutions with NGS expertise are provided.
newhorizonbio.com2013Beijing, China$151.83M
Provider of early cancer screening and testing services
Premium access

Detailed competitors of Yikon Genomics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Yikon Genomics

The website of Yikon Genomics (yikongenomics.com) receives about 4.6K visits a month.

  • Monthly visits
    4.6K
Similar websites

Websites whose visitors overlap most with Yikon Genomics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
qiagen.com
100%
458.2K#105,023View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Yikon Genomics

Premium access

Complete news archive for Yikon Genomics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yikon Genomics

Yikon Genomics was founded in 2012 and raised its 1st funding round 7 years after it was founded.

Yikon Genomics is headquartered in China. It is registered at Beijing, China.

Yikon Genomics is a funded company, having raised a total of $31.26M across 1 funding round to date. The company's 1st funding round was a Series C of $31.26M, raised on Nov 2019.

The primary company behind Yikon Genomics, Yikon Genomics India Private Limited, reported revenue of β‚Ή5.10 Cr for FY 2025, up 400% year on year.

Yikon Genomics was founded in 2012 in Changping District, China, within the genomics sector. Next-generation sequencing is applied to deliver non-invasive prenatal testing and liquid biopsy services. A proprietary MALBAC-NGS platform is utilized for targeted DNA amplification. Kits are supplied for pre-implantation genetic testing, SNP-based tumor profiling, HER2 assessment, and BRCA analysis. Liquid biopsy options are also available to support personalized cancer treatments.

Yikon Genomics's top competitors include Novogene Corporation, Burning Rock and Zhejiang Nuhui Health Technology.

Yikon Genomics has 4 investors. Key investors include Bank of Communications, Yuexiu Capital, Zhongyuan Jiupai Fund, and Jinhe Capital.

Yikon Genomics operates through Yikon Genomics India Private Limited.

The legal entities of Yikon Genomics currently have 2 directors, including Amol Pandurang Jadhav, Vishakha Amol Jadhav.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available